Anti-CD22 Calicheamicin-Inotuzumab Ozogamicin Combined with Venetoclax + Azacitidine in the Treatment of Mixed-Phenotype Acute Leukemia: A Case Report

Documenti analoghi

• CD58 expression does not impact response to inotuzumab ozogamicin in patients with B‐cell acute lymphoblastic leukemia
  di: Rafael Madero‐Marroquin, et al.
  Pubblicazione: (2025-02-01)
• Complete Remission with Inotuzumab Ozogamicin as Fourth-Line Salvage Therapy in a Child with Relapsed/Refractory Acute Lymphoblastic Leukemia
  di: Athanasios Tragiannidis, et al.
  Pubblicazione: (2024-09-01)
• Real‐World Data on Inotuzumab Ozogamicin for Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia: A GRELAL‐Chile Study
  di: Marcela Espinoza, et al.
  Pubblicazione: (2025-09-01)
• Anti-CD22 Calicheamicin-Inotuzumab Ozogamicin Combined with Venetoclax + Azacitidine in the Treatment of Mixed-Phenotype Acute Leukemia: A Case Report
  di: Kongfei Li, et al.
  Pubblicazione: (2024-09-01)
• Guided by target selection, inotuzumab ozogamicin successfully salvaged a patient with refractory follicular lymphoma after anti-CD19 and anti-CD22 CAR T-cell therapy: a case report and literature review
  di: Xin Li, et al.
  Pubblicazione: (2026-02-01)